Example: biology
DRUG NAME: Trastuzumab
CLASSIFICATION: molecular targeted therapy . Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Trastuzumab is a human monoclonal IgG antibody which selectively targets HER2, a human epidermal growth factor receptor (EGFR).
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caBC CANCER HAZARDOUS DRUG LIST (Refer to: Pharmacy Directive VI-80 Hazardous Drug List) The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:
Safe Handling of Hazardous Drugs - BC Cancer
www.bccancer.bc.caA.1 Potential Hazards of Handling Hazardous Drugs..... 1 A.2 Hazardous Drug List.....
British Columbia Cancer Agency POLICY
www.bccancer.bc.caBritish Columbia Cancer Agency ¦ POLICY Title: PREVENTION AND MANAGEMENT OF EXTRAVASATION OF CHEMOTHERAPY Number: III-20 Effective Date: Provincial Systemic Program September 1,1997
Oncology Nutrition High Protein High Energy …
www.bccancer.bc.caHigh Protein High Energy Food Choices 3 Examples of High Protein Foods • All meat (eg. beef, pork, goat, lamb) • Fish and shellfish • All poultry (eg. chicken, turkey, duck)
“Magic” mouthwash explained - BC Cancer
www.bccancer.bc.caFAMILY PRACTICE ONCOLOGY NETWORK JOURNAL / FALL 2014 3 “Magic” mouthwash explained By Dr. Allan Hovan, Provincial Professional Practice Leader,
Symptom Management Guidelines: ORAL …
www.bccancer.bc.caSymptom Management Guidelines: ORAL MUCOSITIS . Definition Oral Mucositis (Stomatitis): An acute inflammation and/or ulceration of the …
Guidelines for Management of CID - BC Cancer
www.bccancer.bc.caDisclaimer Both the format and content of the guidelines will change as they are reviewed and revised on a periodic basis. Any physician using these guidelines to provide
Symptom Management Guidelines: FEVER AND …
www.bccancer.bc.caSymptom Management Guidelines: FEVER AND NEUTROPENIA . Definition • Fever: A single oral temperature of ≥ 38.3° C (101° F) OR a temperature ≥ 38 ° C (100.4 ° F) which lasts more than 1h
Symptom Management Guidelines: XEROSTOMIA
www.bccancer.bc.caSymptom Management Guidelines: XEROSTOMIA. Definition(s) • Xerostomia: abnormal dryness in the mouth characterized by a marked decrease and/or thickening of saliva, may be
Linking the BC Psychosocial Community Oncology …
www.bccancer.bc.caCarolyn Jacob - New Regional Professional Practice Leader at the Centre for the North. We welcome Carolyn Jacob, MSW, RSW to her new role at the BC
Related documents
がんのバイオマーカー - Pmda
www.pmda.go.jpTrastuzumab Emtansine ERBB2 (HER2) Indications and Usage, Warnings and Precautions, Adverse Reactions, ... matched therapy: changes from baseline in tumor measurements (waterfall plot). ... An example of an integrative approach to pathway analysis of a drug-sensitive versus drug-resistant population of patients. Nat. Rev. Clin. Oncol.
DRUG NAME: Trastuzumab emtansine
www.bccancer.bc.caMECHANISM OF ACTION: Trastuzumab emtansine is an antibody -drug conjugate incorporating the monoclonal antibody trastuzumab and emtansine. The emtansine moiety is comprised of two components, DM1, a microtubule inhibitor, and MCC, a thioether linker. Trastuzumab emtansine binds to human epidermal growth factor 2 (HER2) receptors and …
DS-7300 Seminar
www.daiichisankyo.comDS-7300 Mechanism of Action DS-7300 is an antibody-drug conjugate (ADC) composed of a humanized anti–B7- H3 immunoglobulin G1 (IgG1) monoclonal antibody …
SCIENTIFIC DISCUSSION 1. Introduction
www.ema.europa.euTrastuzumab is formulated as a lyophilised powder and each vial is designed to deliver 150 mg trastuzumab. The finished product also includes 3.36 mg L-Histidine HCl, 2.16 mg L-Histidine, 136.2 mg trehalose, dihydrate, and 0.6 mg polysorbate 20. The sterile solution is filled aseptically into 15 ml Type I borosilicate glass vials with 20 mm
Guidelines for the Management of Extravasation of a ...
www.england.nhs.ukMgt of Extravasation of a Systemic Anti-Cancer Therapy including Cytotoxic Agents v1.docx Document Purpose The purpose of this guideline is to provide clear guidance on the causes, prevention, recognition and management of an extravasation of a Systemic Anti-Cancer Therapy used in the treatment of malignant disease in the patient